Pre-made Obiltoxaximab benchmark antibody ( Whole mAb, anti-Anthrax Protective Antigen therapeutic antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Obiltoxaximab biosimilar, Whole Mab: Anti-Anthrax Protective Antigen therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Obiltoxaximab, sold under the brand name Anthim, is a monoclonal antibody medication designed for the treatment of exposure to Bacillus anthracis spores (etiologic agent of anthrax).

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-384-1mg	1mg	3090
GMP-Bios-ab-384-10mg	10mg	Inquiry
GMP-Bios-ab-384-100mg	100mg	Inquiry
GMP-Bios-ab-384-xmg	＞100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Obiltoxaximab biosimilar, Whole Mab: Anti-Anthrax Protective Antigen therapeutic antibody
INN Name	Obiltoxaximab
Target	Anthrax Protective Antigen
Format	Whole mAb
Derivation	Chimeric (Mouse/Human)
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Approved
Est. Status	NFD
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2015
Year Recommended	2016
Companies	Elusys Therapeutics
Conditions Approved	Anthrax
Conditions Active	na
Conditions Discontinued	na
Development Tech	na